Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences:

• 2025 Wells Fargo Healthcare Conference (Boston, MA)
  
  

Hosting 1x1 meetings on Wednesday, September 3

• Morgan Stanley 23^rd Annual Global Healthcare Conference (New York, NY)
  
  

Fireside chat on Monday, September 8 at 3:20 p.m. Eastern Time / 12:20 p.m. Pacific Time, and hosting 1x1 meetings

• H.C. Wainwright 27^th Annual Global Investment Conference (New York, NY)
  
  

Fireside chat on Tuesday, September 9 at 9:30 a.m. Eastern Time / 6:30 a.m. Pacific Time, and hosting 1x1 meetings

Interested parties may access live and archived webcasts of the Morgan Stanley and H.C. Wainwright Conference fireside chat sessions on the company’s investor relations website at investors.absci.com.

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com

Media Contact
press@absci.com